Physician profile
Daniel Peter Kayal
NPI 1629025697
$7,555.30
in general payments reported to CMS, 2019-2025
38 companies · $931 in 2025
The $931 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,032 · 2020: $140 · 2021: $445 · 2022: $1,990 · 2023: $1,499 · 2024: $1,519 · 2025: $931.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,899 · Education: $50.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,898.62 |
| Education | $50.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,734.61 | 2019-2025 | |
| Janssen Biotech, INC. | $690.55 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $417.69 | 2019-2024 | Livdelzi, Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $355.45 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $310.60 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $249.53 | 2019-2025 | |
| Qol Medical, LLC | $231.13 | 2019-2024 | Sucraid |
| Intercept Pharmaceuticals, INC. | $218.40 | 2019-2025 | |
| Genzyme Corporation | $203.28 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $190.39 | 2021-2022 | |
| Daiichi Sankyo INC. | $170.84 | 2022-2024 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $145.08 | 2019-2024 | Dificid |
| Ardelyx, INC. | $140.68 | 2023-2025 | Ibsrela |
| Novo Nordisk INC | $124.99 | 2025 | Wegovy |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kayal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.